A Systemic Inflammatory Index (SII), calculated as neutrophil x platelet/neutrophil count, is also predictive for DFS and OS in breast cancer [81] and was found to be more reliable in human epidermal growth factor receptor-2 positive (HER2+) breast cancer patients compared to other inflammatory markers [82]. This evidence concerns the gene ERBB2 and breast cancer.